| Literature DB >> 35566697 |
Paweł T Dolibog1, Beata Porębska2, Sławomir Grzegorczyn1, Daria Chmielewska3, Andrzej Ślęzak4, Patrycja Dolibog5.
Abstract
The available publications describing the beneficial effects of electrostimulation does not unequivocally confirm the clinical utility of high-voltage electrical stimulation (HVES) in the treatment of the lateral epicondylitis (LE). The aim of this study was the estimation of the effect of HVES on pain intensity and functional efficiency, both in the short and long term in patients with LE. The trial was registered by the Australian and New Zealand Clinical Trials Registry (ACTRN12621001389897). There were 58 patients allocated into two groups: the HVES group (n = 29, mean age 49.9 ± 11.0 years), treated with HVES (pulse duration: 200μs, frequency: 100 Hz, current amplitude in the range of 18-25 mA, voltage amplitude: 100 V), and the NORM group (n = 29, mean age 48.0 ± 12.6 years), who were healthy and untreated patients. The treatments were performed 5 days a week (from Monday to Friday) for two weeks. Treatment progress was measured by the visual analogue scale (VAS) for rest pain, night pain, and pain during activity; the Laitinen Pain Scale (LPS); and hand grip strength (HGS) before and after the treatment, as well as after 3, 6, 12, and 24 weeks. The reduction of pain (according to the VAS and LPS) and increase in the functional condition (according to the HGS) were observed in all HVES patients in the short- and long-term observation. Therefore, the HVES in treatment of LE was found to be effective and safe.Entities:
Keywords: hand grip strength; high-voltage electrical stimulation; lateral epicondylitis; pain intensity; tennis elbow; visual analogue scale
Year: 2022 PMID: 35566697 PMCID: PMC9105087 DOI: 10.3390/jcm11092571
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1The typical characteristics of waveform in HVES (pulse duration: tIMP = 0.01 T; pause duration: tPAUSE = 0.99 T; period: T = tIMP + tPAUSE; duty cycle: tIMP/T.).
Figure 2The CONSORT 2010 flow diagram of patients in the study. Abbreviations: HVES, high-voltage electrical stimulation; NORM, control group.
Demographic and anthropometric characteristics of patients in HVES and NORM groups. p—Mann–Whitney U test; p *—χ2 (chi-squared) test. SD—standard deviation.
| Parameter | HVES Group | NORM Group | |
|---|---|---|---|
| Total ( | 29 | 29 | |
| Gender—female/male ( | 17/12 | 17/12 | 1 * |
| Age (years) | |||
| Mean | 49.9 | 48.0 | |
| SD | 11.0 | 12.6 | |
| Median | 51.0 | 50.0 | 0.769 |
| Range | 29.0–72.0 | 20.0–65.0 | |
| Height (m) | |||
| Mean | 168.8 | 168.0 | |
| SD | 9.1 | 7.7 | |
| Median | 167.0 | 168.0 | 0.781 |
| Range | 153.0–182.0 | 150.0–184.0 | |
| Weight (kg) | |||
| Mean | 76.4 | 74.5 | |
| SD | 16.1 | 15.5 | |
| Median | 75.0 | 70.0 | 0.665 |
| Range | 49.0–110.0 | 55.0–106.0 | |
| Body weight status by World Health Organization standards | |||
| Normal weight (%) | 12 (41) | 12 (41) | |
| Overweight (%) | 13 (45) | 9 (31) | 0.352 * |
| Obesity (%) | 4 (14) | 8 (28) | |
| Affected side | |||
| Right | 19 | - | - |
| Left | 10 |
Figure 3(a) Therapeutic current applied in therapy. (b) Placement of electrodes during therapy.
The dynamometric measurement of the hand grip strength. ICC, interclass correlation coefficient model (for six trials of the hand grip strength). Abbreviations: W0, baseline (before treatment); W1, after treatment; W2, 3 weeks after treatment; W3, 6 weeks after treatment; W4, 12 weeks after treatment; W5, 24 weeks after treatment.
| Group | W0 | W1 | W2 | W3 | W4 | W5 | |
|---|---|---|---|---|---|---|---|
| HVES (kG) | Main effect, | ||||||
| Mean | 24.1 | 30.9 | 34.2 | 36.4 | 36.9 | 37.1 | W0 vs. W1, |
| SD | 13.4 | 12.9 | 12.7 | 11.9 | 11.8 | 12.4 | W0 vs. W2, |
| Median | 22.7 | 29.0 | 31.7 | 31.7 | 31.7 | 31.7 | W0 vs. W3, |
| Min | 2.3 | 8.2 | 13.6 | 20.4 | 22.7 | 20.4 | W0 vs. W4, |
| Max | 49.9 | 54.4 | 57.6 | 61.2 | 57.6 | 58.9 | W0 vs. W5, |
| NORM (kG) | |||||||
| Mean | 34.3 | 34.4 | 34.3 | 33.6 | 34.2 | 34.1 | |
| SD | 10.2 | 9.4 | 9.4 | 9.4 | 9.8 | 9.5 | ICC(2,k) = 0.991 |
| Median | 31.7 | 33.6 | 31.9 | 31.3 | 32.2 | 32.4 | −95% CI ICC(2,k) = 0.988 |
| Min | 18.1 | 19.5 | 19.1 | 18.1 | 17.2 | 18.1 | +95% CI ICC(2,k) = 0.994 |
| Max | 61.7 | 56.7 | 54.0 | 56.0 | 56.0 | 56.0 | |
| <0.001 | 0.134 | 0.638 | 0.534 | 0.564 | 0.600 |
The dynamometric measurement of wrist flexor strength. ICC, interclass correlation coefficient model (for six trials of the wrist flexors strength). Abbreviations: W0, baseline (before treatment); W1, after treatment; W2, 3 weeks after treatment; W3, 6 weeks after treatment; W4, 12 weeks after treatment; W5, 24 weeks after treatment.
| Group | W0 | W1 | W2 | W3 | W4 | W5 | |
|---|---|---|---|---|---|---|---|
| HVES (kG) | Main effect, | ||||||
| Mean | 6.8 | 9.0 | 9.6 | 10.2 | 10.9 | 10.8 | W0 vs. W1, |
| SD | 3.4 | 3.8 | 4.3 | 4.6 | 4.0 | 4.0 | W0 vs. W2, |
| Median | 6.8 | 8.4 | 8.8 | 9.6 | 10.7 | 9.3 | W0 vs. W3, |
| Min | 1.7 | 4.5 | 4.5 | 4.5 | 4.5 | 4.5 | W0 vs. W4, |
| Max | 12.7 | 17.2 | 18.1 | 20.4 | 20.4 | 20.4 | W0 vs. W5, |
| NORM (kG) | |||||||
| Mean | 9.9 | 9.8 | 9.9 | 9.9 | 9.7 | 9.8 | |
| SD | 3.5 | 3.6 | 3.7 | 3.9 | 3.6 | 3.6 | ICC(2,k) = 0.987 |
| Median | 10.0 | 10.0 | 9.9 | 9.7 | 9.7 | 9.7 | −95% CI ICC(2,k) = 0.980 |
| Min | 4.5 | 4.1 | 4.5 | 3.6 | 4.1 | 4.5 | +95% CI ICC(2,k) = 0.991 |
| Max | 18.1 | 17.2 | 18.0 | 22.0 | 18.0 | 18.0 | |
| <0.001 | 0.154 | 0.505 | 0.968 | 0.249 | 0.465 |
The dynamometric measurement of wrist extensor strength. ICC, interclass correlation coefficient model (for six trials of the wrist extensors strength). Abbreviations: W0, baseline (before treatment); W1, after treatment; W2, 3 weeks after treatment; W3, 6 weeks after treatment; W4, 12 weeks after treatment; W5, 24 weeks after treatment.
| Group | W0 | W1 | W2 | W3 | W4 | W5 | |
|---|---|---|---|---|---|---|---|
| HVES (kG) | Main effect, | ||||||
| Mean | 4.1 | 5.9 | 6.7 | 7.4 | 7.7 | 7.8 | W0 vs. W1, |
| SD | 2.9 | 3.3 | 3.7 | 3.9 | 3.7 | 3.8 | W0 vs. W2, |
| Median | 3.4 | 4.5 | 4.5 | 5.4 | 7.0 | 7.5 | W0 vs. W3, |
| Min | 0.4 | 2.3 | 2.3 | 3.2 | 3.6 | 2.3 | W0 vs. W4, |
| Max | 10.4 | 13.6 | 13.6 | 15.9 | 15.9 | 15.9 | W0 vs. W5, |
| NORM (kG) | |||||||
| Mean | 6.6 | 6.7 | 6.5 | 6.5 | 6.6 | 6.6 | |
| SD | 2.6 | 2.6 | 2.2 | 2.3 | 2.4 | 2.3 | ICC(2,k) = 0.991 |
| Median | 6.0 | 6.4 | 6.0 | 6.0 | 6.6 | 6.6 | −95% CI for ICC(2,k) = 0.986 |
| Min | 2.7 | 2.7 | 2.3 | 2.3 | 2.3 | 2.3 | +95% CI for ICC(2,k) = 0.993 |
| Max | 13.6 | 13.6 | 10.9 | 10.9 | 10.9 | 11.3 | |
| <0.001 | 0.049 | 0.493 | 0.989 | 0.510 | 0.313 |
The HGS for patients in the NORM group (34.3 ± 10.2 kG; 336.4 ± 100.0 N) were statistically significantly greater than the HGS in the patients in the HVES group (24.1 ± 13.4 kG; 236.3 ± 131.4 N) only before treatment (p < 0.001). However, in long-term observations, the hand grip strength in the HVES group was slowly increased, and 3 weeks after therapy was at the level of value in the NORM group (34.2 vs. 34.3 kG; 335.4 vs. 336.4 N), and further gradually increased up to 24 weeks after treatment (37.1 vs. 34.1 kG; 368.8 vs. 334.4 N).
The VAS and LPS results of within-group HVES at treatment (points). Abbreviations: W0, baseline (before treatment); W1, after treatment; W2, 3 weeks after treatment; W3, 6 weeks after treatment; W4, 12 weeks after treatment; W5, 24 weeks after treatment.
| Parameter (Points) | HVES | W0 | W1 | W2 | W3 | W4 | W5 | |
|---|---|---|---|---|---|---|---|---|
| The VAS results: | Mean | 5.1 | 1.2 | 0.8 | 0.4 | 0.2 | 0.2 | Main effect, |
| The VAS results: | Mean | 5.6 | 1.4 | 0.9 | 0.7 | 0.4 | 0.3 | Main effect, |
| The VAS results: | Mean | 7.8 | 3.1 | 2.2 | 1.9 | 1.2 | 0.9 | Main effect, |
| The LPS results | Mean | 7.4 | 2.4 | 1.8 | 0.9 | 0.7 | 0.7 | Main effect, |
Figure 4The comparison of changes in VAS points: (a) rest pain; (b) night pain; (c) pain during activity) and (d) LPS scores in the HVES group: before treatment; 0—after treatment; and 3, 6, 12, and 24 weeks after study completion.